“The ability to generate truly complete sequences of chromosomes and genomes is a technical feat that will help us gain a comprehensive understanding of genome function and inform the use of genomic information in medical care.” noted NHGRI Director Eric Green.
Developed in collaboration with researchers and clinicians at the Mayo Clinic, and other partners, Illumina says TruSight provides a turn-key solution to tackle the most critical, and challenging piece of incorporating whole-genome sequencing for the identification of rare genetic diseases.
NIH will fund six new “enhanced diversity clinical sites,” to include: the University of Alabama, the Icahn School of Medicine at Mount Sinai, Cincinnati Children's Hospital Medical Center, Columbia University, the Children’s Hospital of Philadelphia, and the University of Washington Medical Center.
Illumina said it expects BlueBee’s cloud capability to lower the cost of storing, sharing and managing the genomic data that streams from Illumina’s installed base of more than 15,000 sequencing systems.
The PODS system was developed at MD Anderson to aid oncologist in therapeutic decision making for their patients at the point of care based on existing evidence of effective treatment regimens. It provides clinicians with a list of approved therapies and matches the patient to available clinical trials based on the genetic profile of their tumor.
Seven Bridges will apply to AlloSure the Seven Bridges Bioinformatics Ecosystem, a solution created to enable scientists to simplify complex analysis and reduce time to result by working in a common environment and automating concurrent processing of workflows efficiently and collaboratively.
The new center seeks to provide Mount Sinai with data analytic solutions to combat current and future threats of COVID-19, as well as rapidly develop digital health products with real-time predictive and preventive capabilities.
In the new approach, patients are provided an additional informed consent document regarding sharing their information that research participants can choose to sign. This additional, or special consent, is additive to the standard informed consent papers required for participating in a research project.
The companies said they will train, model, and expand insights continuously using machine learning and artificial intelligence, with the goal of enabling early identification of people at high risk for PTSD and other behavioral health conditions based on their biomarkers.
The intention is to use the combined expertise in functional genomics and digital therapeutics to develop a range of health apps with pain management and COVID-19 the initial foci.